ACE2 and COVID-19: Furthermore, the increase in ACE2 activity demonstrated in patients with hypertension, either due to the pathophysiology of hypertension itself67 or the administration of ACEIs/ARBs as antihypertensive medications,68 could at least partially explain some of our study findings as why ACEIs/ARBs had significant greater impact on certain COVID‐19 clinical outcomes (i.e. mortality and death/ICU admission) only among studies that included patient with hypertension.